You are here: / / Baricade-Preserve

Baricade-Preserve Study

Recruiting until: 31-Mar-2027

Baricitinib to Preserve Beta Cell Function in Participants Newly Diagnosed with Type 1 Diabetes Aged ≥1 to <36 Years (BARICADE-Preserve)

Recruiting sites:

  • Dr Maitrayee Choudhury, University Hospital of Wales (Adults)
  • Prof Loredana Marchovecchio, Addenbrooke’s Hospital (Paediatrics and Adults)
  • Dr Georgina Russell, Southmead Hospital (Adults)
  • Prof Sam Philip, Aberdeen Royal Infirmary (Adults)
  • Dr Nicola Trevelyan, Southampton General Hospital (Paediatrics and Adults)

Sites opening soon:

  • Dr Renuka Dias, Birmingham Children’s Hospital (Paediatrics)
  • Prof Parth Narendran, Queen Elizabeth Hospital (Adults)
  • Prof Katharine Owen, Churchill Hospital (Adults and Paediatrics)

Summary

This study is testing whether a medicine called baricitinib can help protect the insulin‑producing cells in the pancreas in people who have recently been diagnosed with type 1 diabetes. The aim is to slow down the damage to these cells, which may help people make more of their own insulin for longer.

Aim

When someone is first diagnosed with type 1 diabetes, they often still make some of their own insulin, but this usually reduces over time. This study aims to find out whether baricitinib can help preserve the body’s remaining insulin‑producing cells, helping to improve blood sugar control and reduce the amount of insulin needed.

Eligibility to take part

  • Are aged 1 year to under 36 years
  • Have been diagnosed with type 1 diabetes within the last 100 days
  • Still make a small amount of your own insulin
  • Are willing to use a continuous glucose monitor (CGM) during the study

If you are interested in taking part, please click the “Get Involved” button below:

Get Involved

What will I be asked to do?

  • Take either baricitinib or a placebo (a dummy treatment), in the form of either a tablet or liquid, once a day for up to one year
  • Continue your usual insulin treatment
  • Attend regular study visits for check‑ups, blood tests, and diabetes assessments
  • Wear a continuous glucose monitor to track blood sugar levels
  • Have tests to measure how much insulin your body is still making

Who is running this study?

  • Sponsor: Eli Lilly and Company
  • Study type: International commercial clinical research study
  • Study visits: Conducted at NHS hospitals in the UK
  • Oversight: The study has been reviewed by an independent ethics committee and is monitored by independent safety experts

Site Locator